![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
KL Preston, GE Bigelow and IA Liebson
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.
The subjective, physiological and behavioral effects of nalbuphine, an opioid mixed agonist/antagonist analgesic, naloxone and hydromorphone were studied on adult, male, methadone-dependent volunteers living on a clinical research ward. The purpose was to assess nalbuphine's agonist properties vs. antagonist properties relative to a standard agonist (hydromorphone) and a standard antagonist (naloxone) in opioid- dependent subjects. Drug conditions included saline placebo, nalbuphine hydrochloride (0.375, 0.75, 1.5, 3 and 6 mg), naloxone hydrochloride (0.1 and 0.2 mg) and hydromorphone hydrochloride (4 and 8 mg). Drug conditions, given by i.m. injection, were tested in five subjects under double-blind conditions in 2.5 hr experimental sessions. Physiologic measures were monitored continuously before and for 2 hr after drug administration: pupil diameter and subject- and observer-rated behavioral responses were measured intermittently over this same period. Hydromorphone increased ratings significantly on subjective measures typical of morphine-like effects. Naloxone precipitated opioid abstinence which was measurable on several subject- and observer-rated behavioral measures and physiological measures. Nalbuphine produced effects which were qualitatively similar to the effects of naloxone and showed no evidence of opioid agonist effects in these methadone- dependent subjects. The withdrawal syndrome precipitated by nalbuphine was indistinguishable from that produced by naloxone.
This article has been cited by other articles:
|
|
 |
|
  K. M. Raehal, J. J. Lowery, C. M. Bhamidipati, R. M. Paolino, J. R. Blair, D. Wang, W. Sadee, and E. J. Bilsky In Vivo Characterization of 6{beta}-Naltrexol, an Opioid Ligand with Less Inverse Agonist Activity Compared with Naltrexone and Naloxone in Opioid-Dependent Mice J. Pharmacol. Exp. Ther., June 1, 2005; 313(3): 1150 - 1162. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Walker, M. J. Picker, A. Granger, and L. A. Dykstra Effects of Opioids in Morphine-Treated Pigeons Trained to Discriminate among Morphine, the Low-Efficacy Agonist Nalbuphine, and Saline J. Pharmacol. Exp. Ther., July 1, 2004; 310(1): 150 - 158. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Smith and H. Guly Nalbuphine and slow release morphine BMJ, June 12, 2004; 328(7453): 1426 - 1426. [Full Text] [PDF]
|
|
|
|
|
|
D. J. Walker and J. P. Zacny Subjective, Psychomotor, and Physiological Effects of Cumulative Doses of Opioid µ Agonists in Healthy Volunteers J. Pharmacol. Exp. Ther., June 1, 1999; 289(3): 1454 - 1464. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. M. van Ree, M. A. F. M. Gerrits, and L. J. M. J. Vanderschuren Opioids, Reward and Addiction: An Encounter of Biology, Psychology, and Medicine Pharmacol. Rev., June 1, 1999; 51(2): 341 - 396. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Zacny, K. Conley, and J. Galinkin Comparing the Subjective, Psychomotor and Physiological Effects of Intravenous Buprenorphine and Morphine in Healthy Volunteers J. Pharmacol. Exp. Ther., September 1, 1997; 282(3): 1187 - 1197. [Abstract] [Full Text]
|
|
|
|
|
|
J. P. Zacny, K. Conley, and S. Marks Comparing the Subjective, Psychomotor and Physiological Effects of Intravenous Nalbuphine and Morphine in Healthy Volunteers J. Pharmacol. Exp. Ther., March 1, 1997; 280(3): 1159 - 1169. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
